HNF4ApR309C -/- 2-4

General

Cell Line

hPSCreg Name
BIONi010-C-12
Alternative name(s)
HNF4ApR309C -/- 2-4
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
BIONi010-C
(BIONi010-C, K3P53)
BIONi010-C-10
(HNF1AP291fsinsC +/- 54-5)
BIONi010-C-11
(HNF1AP291fsinsC -/- 66-1)
BIONi010-C-13
(BIONi010-C + NGN2 #I7-26)
BIONi010-C-2
(BIONi010-C ApoE E3/E3 #H8 P32)
BIONi010-C-3
(BIONi010-C ApoE KO #KO30 P30)
BIONi010-C-15
(BIONi010-C +dox inducible NGN2-GFP)
BIONi010-C-25
(BIONi010-C heterozygous TREM2 KO)
BIONi010-C-4
(BIONi010-C ApoE E4/E4 #B44 P27)
BIONi010-C-5
(BIONi010-C CD33 E2del #N14 P26)
BIONi010-C-6
(BIONi010-C ApoE E2/E2)
BIONi010-C-7
(BIONi010-C Trem2 R47H)
BIONi010-C-8
(BIONi010-C Trem2 T66M, #Y5-80)
BIONi010-C-9
(BIONi010-C CD33 KO)
BIONi010-C-17
(BIONi010-C TREM2 KO)
BIONi010-C-51
(BIONi010-C TNNI3-mCherry reporter)
BIONi010-C-18
(BIONi010-C TBK1 KO)
BIONi010-C-19
(BIONi010-C IKBKE KO)
BIONi010-C-52
(BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6))
BIONi010-C-53
(BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2))
BIONi010-C-55
(BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74)
BIONi010-C-24
(BIONi010-C Dox a-syn)
BIONi010-C-43
(BIONi010-C + aSNCA-wt AAVS1)
BIONi010-C-44
(BIONi010-C + aSNCA-A53T AAVS1)
BIONi010-C-54
(BIONi010-C with an APOE 4/4 genotype (with two functional alleles in contrast to BIONi010-C-4))
BIONi010-C-45
(BIONi010-C iCRE AAVS1 GBA1 LoxP EX5-6)
BIONi010-C-41
(BIONi010-C + iNGN2 Two-plasmid system/CRISPR-2)
BIONi010-C-42
(BIONi010-C + iCRE AAVS1)
BIONi010-C-64
(BIONi010-C-T2A-Nanoluciferase reporter cl. 29)
BIONi010-C-49
(BIONi010-C + synapsin-m2rtTA + SNCA-wt)
BIONi010-C-50
(BIONi010-C + synapsin-m2rtTA + SNCA-A53T)
BIONi010-C-56
(BIONi010-C-A713T-C25)
BIONi010-C-57
(BIONi010-C-A713T-C42)
BIONi010-C-58
(BIONi010-C-A713T-C1)
BIONi010-C-59
(BIONi010-C-A713T-C33)
BIONi010-C-60
(BIONi010-C-R589C-C7)
BIONi010-C-61
(BIONi010-C-R589C-C16)
BIONi010-C-62
(BIONi010-C-R589C-C5)
BIONi010-A
(K1P53)
BIONi010-B
(K2P53, BIONi010-B)
UCSFi001-A-49
(YH653-MUT-1C8-HET, DYT1-HET-1C8)
UCSFi001-A-50
(YH653-MUT-H6-HET, DYT1-HET-H6)
UCSFi001-A-51
(YH653-MUT-2F2-HOMO, DYT1-HOMO-2F2)
DHMi005-A-5
(L_mut_FLAG Clone 4)
DHMi005-A-6
(L_mut_FLAG Clone 14)
DHMi005-A-7
(L_mut_FLAG Clone 15)
CEBe033-A-8
(SA001_KO_HGPRT_1)
Last update 7th March 2023
Notes No larger chromosomal aberrations to be reported. Chr22: 1,4Mbp duplication in q11.23
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Bioneer (BION)
Contact:
Bioneer (BION)
Owner Bioneer (BION)
Distributors
Derivation country Denmark

External Databases

BioSamples SAMEA104619383
EBiSC BIONi010-C-12
Cellosaurus CVCL_RM86
CLO CLO_0102726
Wikidata Q54796756

General Information

Projects
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information

Sex male
Ethnicity Black or African-American

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105780

Ethics

Also have a look at the ethics information for the parental line BIONi010-C .
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

The source cell information can be found in the parental cell line BIONi010-C.

Reprogramming method

Vector type Non-integrating
Vector Episomal
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Method documentation
HNF4A 2-4 flow.tif
Flow cytometry of undifferentiated cells

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Passage number: 12
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
MODY
Synonyms
  • Maturity-onset diabetes of the young
Genetic modifications
HNF4A (target)
Isogenic modification
20q13.12
NM_175914.4:c.925C>T
NP_787110.2:p.(p.Arg309Cys)
Homozygous
A Cytocine to Tyrosine mutation was introduced into both alleles of exon 8 in HNF4A resulting in a mutation previously shown to cause MODY1 in patients.
Mutated